Trial Profile

A Phase Ib/IIa Randomized, Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Antiviral Activity of BRII-179 (VBI-2601) among Subjects with Chronic Hepatitis B

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VBI 2601 (Primary)
Indications Hepatitis B
Focus Adverse reactions; Proof of concept
Sponsors Brii Biosciences

Most Recent Events

08 Nov 2021 According to a VBI Vaccines media release, data from this trial were published in JHEP Reports, an open access companion title to Journal of Hepatology in September.
26 Jun 2021 Results presented at The International Liver Congress 2021
23 Jun 2021 According to a Brii Biosciences media release, Man-Fung Yuen is the principal investigator of the study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com